Author | Year | Country | No. of MSC group | No. of control group | AAA model | Animal species | MSC source | Cell compatibility | Intervention route | Total dose (cells) | Control | Follow-up duration (days) |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Hashizume [28] | 2011 | Japan | 7 | 6 | AngII | apoE−/− mice | Bone marrow | Allogenic | Perivascular | 1*105 | NS | 28 |
Sharma [15] | 2012 | USA | 6 | 8 | Elastase | C57BL/6 mice | Placenta | Xenogenic | Intravenous | 1*106 | NS | 14 |
Fu-1 [27] | 2013 | Japan | 10 | 5 | AngII | apoE−/− mice | Bone marrow | Allogenic | Intravenous | 1*106 | Saline | 28 |
Fu-2 [27] | 2013 | Japan | 12 | 5 | AngII | apoE−/− mice | Bone marrow | Allogenic | Intravenous | 4*106 | Saline | 28 |
Schneider-1 [32] | 2013 | France | 6 | 3 | Xenograft | Fischer rats | Bone marrow | Allogenic | Intraluminal | 1*106 | medium | 7 |
Schneider-2 [32] | 2013 | France | 5 | 3 | Xenograft | Fischer rats | Bone marrow | Allogenic | Intraluminal | 1*106 | medium | 28 |
Blose [21] | 2014 | USA | 7 | 6 | Elastase | C57BL/6 mice | Adipose tissue | Allogenic | Perivascular | 1*105 | Saline | 9 |
Yamawaki-Ogata-1 [30] | 2014 | Japan | 10 | 10 | AngII | apoE−/− mice | Bone marrow | Allogenic | Intravenous | 1*106 | Saline | 14 |
Yamawaki-Ogata-2 [30] | 2014 | Japan | 7 | 6 | AngII | apoE−/− mice | Bone marrow | Allogenic | Intravenous | 1*106 | Saline | 28 |
Yamawaki-Ogata-3 [30] | 2014 | Japan | 6 | 5 | AngII | apoE−/− mice | Bone marrow | Allogenic | Intravenous | 1*106 | Saline | 56 |
Zidi [33] | 2015 | France | 6 | 6 | Xenograft | Fischer rats | Bone marrow | Allogenic | Intraluminal | 1*106 | NS | 7 |
Davis-1 [22] | 2015 | USA | 11 | 4 | Elastase | C57BL/6 mice | Bone marrow | Allogenic | Intravenous | 9 × 106 | NS | 14 |
Davis-2 [22] | 2015 | USA | 9 | 4 | Elastase | C57BL/6 mice | Bone marrow | Allogenic | Intravenous | 9 × 106 | NS | 14 |
Sharma [23] | 2016 | USA | 8 | 8 | Elastase | C57BL/6 mice | Umbilical cord | Xenogenic | Intravenous | 1*106 | NS | 14 |
Xie-1 [25] | 2017 | USA | 4 | 4 | Elastase | C57BL/6 mice | Adipose tissue | Xenogenic | Intravenous | 1*106 | PBS | 4 |
Xie-2 [25] | 2017 | USA | 5 | 5 | Elastase | C57BL/6 mice | Adipose tissue | Xenogenic | Intravenous | 1*106 | PBS | 7 |
Xie-3 [25] | 2017 | USA | 4 | 4 | Elastase | C57BL/6 mice | Adipose tissue | Xenogenic | Intravenous | 1*106 | PBS | 14 |
Yamawaki-Ogata [31] | 2017 | Japan | 5 | 5 | AngII | apoE−/− mice | Bone marrow | Allogenic | Intravenous | 1*106 | Saline | 14 |
Hosoyama-1 [29] | 2018 | Japan | 24 | 8 | Elastase CaCl2 | SCID mice | Bone marrow | Xenogenic | Intravenous | 6*104 | PBS | 7, 14, 21 |
Hosoyama-2 [29] | 2018 | Japan | 24 | 8 | Elastase CaCl2 | SCID mice | Bone marrow | Xenogenic | Intravenous | 6*104 | PBS | 28, 35, 42, 56, 64 |
Parvizi [36] | 2018 | Netherlands | 6 | 6 | Elastase CaCl2 | Fischer rats | Adipose tissue | Allogenic | Perivascular | 2*106 | NS | 14 |
Spinosa [24] | 2018 | USA | 12 | 12 | Elastase | C57BL/6 mice | Umbilical cord | Xenogenic | Intravenous | 1*106 | NS | 14 |
Zidi [34] | 2018 | France | 6 | 6 | Xenograft | Fischer rats | Bone marrow | Allogenic | Intraluminal | 1*106 | NS | 7 |
Zhou [35] | 2019 | China | 8 | 8 | AngII | apoE−/− mice | Bone marrow | Allogenic | Intravenous | 2*106 | medium | 14 |
Wen-1 [16] | 2020 | China | 10 | 5 | Elastase | SD rats | Umbilical cord | Xenogenic | Intravenous | 1*106 | Saline | 7 |
Wen-2 [16] | 2020 | China | 10 | 5 | Elastase | SD rats | Umbilical cord | Xenogenic | Intravenous | 1*106 | Saline | 14 |
Akita-1 [26] | 2021 | Japan | 10 | 5 | AngII | apoE−/− mice | Bone marrow | Allogenic | Intravenous | 1*106 | Saline | 14 |
Akita-2 [26] | 2021 | Japan | 10 | 5 | AngII | apoE−/− mice | Bone marrow | Allogenic | Intravenous | 1*106 | Saline | 14 |